Cargando…
Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions
Antibody drug conjugates (ADCs) are novel medications that combine monoclonal antibodies with cytotoxic payloads, enabling the selective delivery of potent drugs to cancer cells expressing specific surface antigens. This targeted strategy seeks to optimize treatment effectiveness while reducing the...
Autores principales: | Mark, Cynthia, Lee, Jin Sun, Cui, Xiaojiang, Yuan, Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531043/ https://www.ncbi.nlm.nih.gov/pubmed/37762027 http://dx.doi.org/10.3390/ijms241813726 |
Ejemplares similares
-
CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions
por: Lee, Jin Sun, et al.
Publicado: (2023) -
Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions
por: Yang, Tinglin, et al.
Publicado: (2023) -
Current Status: Site-Specific Antibody Drug Conjugates
por: Schumacher, Dominik, et al.
Publicado: (2016) -
Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022) -
Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives
por: Martín-Sabroso, Cristina, et al.
Publicado: (2021)